Results 191 to 200 of about 96,642 (272)

Efficacy and safety of fasinumab in an NSAID-controlled study in patients with pain due to osteoarthritis of the knee or hip. [PDF]

open access: yesBMC Musculoskelet Disord
DiMartino SJ   +19 more
europepmc   +1 more source

Rapid and Sustained Improvement of Lichen Planus Pemphigoides With the JAK1 Inhibitor Upadacitinib

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Lichen planus pemphigoides (LPP) is a rare autoimmune blistering disorder characteris ed by lichenoid plaques and blister formation. Current treatments are often ineffective, and there is a lack of standardised guidelines. The disease's pathogenesis involves both T‐cell‐mediated lichenoid dermatitis and autoantibody formation, presenting ...
Louise Gueissaz   +2 more
wiley   +1 more source

The Cognitive Footprint of Medication Use. [PDF]

open access: yesBrain Behav
Pinilla MS   +4 more
europepmc   +1 more source

Lack of Evidence for the Efficacy of Antifungal Medications to Treat Atopic Dermatitis: A Systematic Review

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is characterised by immune dysregulation and skin‐barrier dysfunction, which can predispose to microbial dysbiosis and skin infections. Fungi, particularly Malassezia, are common skin colonisers in AD patients and may exacerbate the condition.
Luis F. Andrade   +8 more
wiley   +1 more source

Management of Mild‐to‐Moderate Atopic Dermatitis With Topical Treatments by Dermatologists: A Questionnaire‐Based Study

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a chronic, immune‐mediated, inflammatory skin disorder affecting a heterogeneous population. Most patients with mild‐to‐moderate AD are treated with topical medication. Objectives To gain an understanding of the management of mild‐to‐moderate AD with topical treatments by examining the practices of ...
Lawrence F. Eichenfield   +14 more
wiley   +1 more source

A Case of Anti‐TNFα Therapies Induced Lupus Panniculitis Successfully Improved With a JAK Inhibitor (Baricitinib)

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Lupus erythematosus panniculitis (LEP) is a rare variant of cutaneous lupus erythematosus (1%–3% of CLE). There are two case reports to date in the literature of LEP potentially triggered by anti‐TNF‐α therapies. Clinically, it is characterised by tender, erythematous subcutaneous indurated nodules or plaques on fatty body areas.
Cristina Grechin   +4 more
wiley   +1 more source

Medication use and risk of reflux oesophagitis. [PDF]

open access: yesBMJ Open Gastroenterol
Ueta R   +15 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy